<DOC>
	<DOCNO>NCT01822080</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety dienogest 2 mg oral tablet treatment endometriosis . There 2 study phase : double-blind , randomize , placebo-controlled , parallel-group phase 24 week , open-label extension phase 2 mg DNG daily p.o . 28 week subject complete double-blind phase , irrespective treatment assignment first study phase .</brief_summary>
	<brief_title>Phase 3 Study Dienogest Treatment Endometriosis Chinese Patients</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>Women 18 45 year age , inclusive Women endometriosis confirm laparoscopy laparotomy within ten year later 2 week Screening Visit A score least 30 100 mm visual analog scale ( VAS ) endometriosisassociated pelvic pain Screening Visit Baseline Visit Good general health ( except finding related endometriosis , without infertility ) , evidence medical history complete physical gynecological examination Willingness use barrier method contraception require Pregnancy lactation ( less three month since delivery , abortion , lactation start treatment ) Wish pregnancy within intend treatment period Before menarche menopause Amenorrhea ( three consecutive month six month screen ) Undiagnosed abnormal genital bleeding Previous/use hormonal agent Any disease condition may worsen hormonal treatment Signs and/or symptom therapyresistant endometriosis despite one prior attempt drug treatment surgical therapy Need primary surgical treatment endometriosis Regular use pain medication due underlying disease Contraindication supportive analgesic medication ( ibuprofen )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Dienogest</keyword>
</DOC>